title: Evidence for supraspinal nervous control of external anal sphincter motility in the cat.
abstract: The aim of this study was to investigate the role of noradrenergic descending nervous pathways in external anal sphincter motility. For this purpose, the effects of intravenously injected adrenoceptor antagonist and agonist on the tonic electrical activity of this sphincter were studied in anesthetized cats. The effects of stimulating the region of the locus coeruleus and the effects of intravenous, intracerebroventricular and intrathecal injection of the above drugs on the electromyographic responses of this muscle to pudendal nerve stimulation were also investigated. The tonic sphincteric activity and the reflex response triggered by electrically stimulating pudendal afferent nerve fibers were inhibited by alpha1-adrenoceptor antagonist nicergoline and enhanced by alpha1-adrenoceptor agonist phenylephrine. Stimulation of the locus coeruleus area either inhibited or enhanced the reflex responses. Intracerebroventricular and intrathecal injection of the alpha2-adrenoceptor agonists, morphine and leu-enkephalin decreased the amplitude of these reflex responses. All the effects of opioids were blocked by naloxone and by spinalization performed at the cervical and lumbar levels. The direct response elicited by stimulating the sphincteric motor axons was not affected either by these drugs or by the brainstem stimulation. These results suggests the existence of a pontine neuronal network controlling the motility of the external anal sphincter via noradrenergic and opioid neurons.
authors.affiliation: Laboratoire de Neurobiologie des Fonctions Végétatives, Faculté de Saint-Jérôme, B.P. 352, Avenue Escadrille Normandie Niemen, 13397 Marseille Cedex 20, France.
authors.forename: A
authors.initials: A
authors.lastname: Abysique
authors.forename: P
authors.initials: P
authors.lastname: Orsoni
authors.forename: M
authors.initials: M
authors.lastname: Bouvier
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D001003:Anal Canal / Q000187:drug effects / Q000294:innervation* / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D000068438:Brimonidine Tartrate; D002415:Cats; D003000:Clonidine / Q000494:pharmacology; D004525:Efferent Pathways / Q000502:physiology; D004558:Electric Stimulation; D004576:Electromyography; D004743:Enkephalin, Leucine / Q000494:pharmacology; D005260:Female; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008125:Locus Coeruleus / Q000502:physiology*; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D009530:Nicergoline / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010525:Peripheral Nerves / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D013116:Spinal Cord / Q000502:physiology* / Q000601:surgery
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D009294:Narcotics; D011810:Quinoxalines; D010656:Phenylephrine; D000068438:Brimonidine Tartrate; D004743:Enkephalin, Leucine; D009020:Morphine; D009530:Nicergoline; D003000:Clonidine; D009638:Norepinephrine; D011224:Prazosin